Free tool
FAERS Monitor: Tyrvaya
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213978 or its brand name (Tyrvaya, Varenicline Tartrate). Reports on generic versions are filed under their own applications.
Reports
6,231
Serious
1,606
26% of reports
Hospitalization
519
Death reported
71
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sneezing749
- nausea586
- drug ineffective473
- vomiting398
- depression364
- headache311
- nasal discomfort263
- product delivery mechanism issue252
- rhinorrhoea236
- suicidal ideation225
- nightmare213
- abnormal dreams212
- cough207
- eye pain200
- insomnia199
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 68 |
| 2008 | 839 |
| 2009 | 478 |
| 2010 | 187 |
| 2011 | 45 |
| 2012 | 66 |
| 2013 | 31 |
| 2014 | 33 |
| 2015 | 53 |
| 2016 | 40 |
| 2017 | 45 |
| 2018 | 51 |
| 2019 | 65 |
| 2020 | 54 |
| 2021 | 53 |
| 2022 | 654 |
| 2023 | 806 |
| 2024 | 1,555 |
| 2025 | 649 |
| 2026 | 459 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,928 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product delivery mechanism issueSignal | 252 | 165.9 | 146.6 | 39,231 |
| sneezingSignal | 749 | 116.6 | 108.9 | 82,935 |
| nasal discomfortSignal | 263 | 115.8 | 102.7 | 28,835 |
| abnormal dreamsSignal | 212 | 26.1 | 22.9 | 5,062 |
| nightmareSignal | 213 | 20.9 | 18.3 | 3,998 |
| rhinorrhoeaSignal | 236 | 12.4 | 10.9 | 2,452 |
| eye painSignal | 200 | 12.0 | 10.5 | 2,005 |
| suicidal ideationSignal | 225 | 8.3 | 7.3 | 1,443 |
| depressionSignal | 364 | 5.4 | 4.9 | 1,315 |
| vomitingSignal | 398 | 2.9 | 2.6 | 490 |
| insomniaSignal | 199 | 2.5 | 2.2 | 184 |
| nauseaSignal | 586 | 2.5 | 2.3 | 546 |
| coughSignal | 207 | 2.5 | 2.2 | 186 |
| headache | 311 | 1.7 | 1.5 | 86 |
| drug ineffective | 473 | 1.2 | 1.1 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.